pharmaphorum

NOVEMBER 30, 2022

Veeva Systems invited pharmaphorum to attend its industry summit in Madrid this week, a huge event that gathered together over 1,000 individuals from life sciences and pharma. The question is, how can the journey there be accelerated, when on the horizon awaits a life sciences future very much immersed in speciality medicine?

Life Science 97

Life Science Pharma Companies Sales Marketing 97

pharmaphorum

JANUARY 6, 2022

The latest pharma company to make a move for an mRNA specialist is Germany’s Merck KGaA, which has offered a $780 million cash buyout to US biotech Exelead. Outsourcing services are on of the pillars of Merck’s business, delivered via its process solutions unit, part of the group’s life sciences division.

Vaccination 97

Vaccination Vaccine Manufacturing Life Science 97

pharmaphorum

NOVEMBER 15, 2022

On 14th November, investors and life science & healthcare executives descended on London’s famed Old Billingsgate building to attend LSX’s Inv€$tival Showcase, part of Europe’s biggest dedicated healthcare investment week. How healthcare innovators are weathering market conditions.

Life Science 84

Life Science Pharma Companies Marketing Production 84

Drug Discovery World

OCTOBER 16, 2023

Dr Tralau-Stewart says: “Indeed, many academic institutions have established new ways of supporting the discovery pipeline, providing tech transfer offices to support licensing, and entrepreneurship and start-up support through fundraising, accelerators, and incubators.

Drugs 75

Drugs Life Science Gene Therapy Genome 75

Pharma Business Blog

MARCH 16, 2022

Happy to share the following Article of Chemie Pharma Innovation with you (German only): [link]. Dr. Sandra Ragaz , Partner Leader Pharma & Life Science VAT Switzerland Tel: +41 58 792 44 69 sandra.ragaz@pwc.ch. Der Beitrag The Pharma Gamechanger erschien zuerst auf Welcome. Have a pleasant reading.

Life Science 52

Life Science Licensing Licensing Pharma Companies 52

pharmaphorum

SEPTEMBER 18, 2020

But although it was dubbed a “dangerous game”, some companies came out on top… On 6th April 1999, two companies with similar science-based cultures and a shared vision of the pharmaceutical industry came together to form what’s now considered as one of the top ten pharma companies in the world: AstraZeneca.

Pharma Companies 116

Pharma Companies Sales Vaccination Vaccine 116

pharmaphorum

DECEMBER 16, 2022

Of significant interest to the pharma industry are the suggestions in the draft text that money granted for research on infectious diseases could include specifications on how eventual products could be marketed.

Vaccination 86

Vaccination Vaccine Production Licensing 86

pharmaphorum

MARCH 26, 2021

The UK Government and EU Commission trumpeted their Brexit trade deal, struck at the end of December, as ‘comprehensive’, the ‘biggest yet’ But a closer inspection of the EU-UK Trade and Cooperation Agreement (TCA) renders these statements largely illusory for the pharma sector. Medical devices do not feature at all.

Production 102

Production Medicine Marketing Regulation 102

pharmaphorum

MAY 14, 2021

This article appears in our digital magazine, Deep Dive: Market Access 2021. It is also possible that companies may prefer to enter the EU market through the EMA process and avoid additional processes involving the MHRA and NICE. It’s important to remember that the UK market represents only 2.5%

Marketing 59

Marketing Regulation Medicine Life Science 59

pharmaphorum

MAY 27, 2022

There is a huge opportunity for pharma companies to capitalise on by focusing on increased DEI in clinical trials. Underrepresentation is multifactorial, so concerted efforts from life science companies are required to address inequitable healthcare. What comes next?

Clinical Trials 80

Clinical Trials Clinical Trials Trials Packaging 80

XTalks

DECEMBER 13, 2023

Now, let’s delve into the list of the top ten fastest growing biotech companies in 2023, ranked by their compound annual growth rate (CAGR). These companies were identified through The Americas’ Fastest-Growing Companies 2023 list by the Financial Times. vaccine, mRNA-1273.815. million, compared to $1.1

Genetics 111

Genetics Vaccination Vaccine DNA 111

XTalks

MARCH 22, 2023

In October 2022, Xtalks celebrated two decades of bringing diverse stakeholders in the life science industry together through first holding physical events, then soon after, hosting exclusively online events. In that time, we’ve gone from running 25 webinars each year to over 400, working with more than 800 expert speakers each year.

Life Science 97

Life Science Drugs FDA Approval Vaccination 97

Drug Discovery World

OCTOBER 7, 2022

It is about going faster in progressing our innovation to market, taking things further along the value chain as we de-risk the early science. It’s about working together with our partners in the life science sector to get world class innovations to patients. . This is about changing how we operate. Hamish Ryder.

HR 52

HR Research Drugs Development 52

Pharmaceutical Technology

JANUARY 25, 2023

After a tumultuous year that weathered the continued impact of a bear market , many in biotech are looking for signs of improvement in 2023. News of layoffs and restructuring have evoked concerns that 2023 could be a year of attrition that will push companies to prioritise key candidates and hold onto their finances.

Marketing 173

Marketing Life Science Pharma Companies Licensing 173

Pharmaceutical Technology

MAY 26, 2023

After raising $125m in 2021 to redevelop the facility, more recently Touchlight secured an additional $17.3m (£14m) from the UK government’s Life Sciences Innovative Manufacturing Fund to accelerate its expansion plans and scale-up equipment. Rapid production will potentially enable researchers to overcome an industry bottleneck.

DNA 130

DNA Manufacturing Gene Therapy Gene 130

XTalks

FEBRUARY 15, 2024

US Senator Bernie Sanders, who chairs the Health, Education, Labor, and Pensions (HELP) Committee, managed to bring CEOs of major American pharma companies to a committee hearing to discuss exorbitant US drug pricing. It’s because we have exceedingly high prices at the outset that there’s an attractive market for middlemen to enter.

Drugs 52

Drugs Pharma Companies Pharmacy Regulation 52